Table 2.
Up-to-date drugs that have implications on Wnt/β-catenin signaling in HCC.
| Drug | Possible Mechanisms on Wnt Signal | Cells Models | References |
|---|---|---|---|
| Shizukaol D Chloranthus serratus |
Unknown | SMMC-7721 SK-HEP1 HepG2 |
[116] [116] [116] |
| Curcumin | Inhibiting GPC3/TPA-induced Wnt signal activation | HepG2 Hep3B |
[133] [133] |
| Pimozide | Unknown | Hep3B HepG2 |
[135] [135] |
| Ethacrynic acid | Unknown | Hep3B HepG2 |
[136] [136] |
| Epigallocatechin-3-gallate | Inhibition of Wnt signaling (decreasing c-myc expression and causing the induction of SFRP1) in HB | [102] | |
| ICG-001 | Disruption β-catenin-CREB binding in HB | HuH6 HepT1 |
[138] |
| Salinomycin FH-535 |
Increasing intracellular Ca2+ levels Inhibition of β-catenin signaling and peroxisome proliferator-activated receptor (PPAR) in HCC |
HepG2 BEL-7402 |
[116] [116] [128] |
In vitro studies prospecting a combination target therapy for Wnt/β-catenin signaling using small molecules in combination with selective inhibitors, natural compounds and repurposed drugs, showing anticancer effects.